癌症研究
泛素连接酶
化学
下调和上调
基因沉默
泛素
表观遗传学
淋巴瘤
弥漫性大B细胞淋巴瘤
癌变
组蛋白
细胞生物学
细胞生长
降级(电信)
甲基转移酶
转录因子
效应器
基因表达调控
肿瘤进展
HEK 293细胞
作者
Yongcheng Sun,Bing Xiu,Miao Zhou,Shujun Yang,Zhijuan Xu,Zanzan Wang,Ping Zhang,Lixia Sheng,Guifang Ouyang,Aibin Liang
摘要
Diffuse large B-cell lymphoma (DLBCL) is the most common and clinically aggressive subtype of non-Hodgkin lymphoma, yet key molecular drivers remain incompletely defined. Here, we identify the tripartite motif E3 ligase TRIM37 as a disease-relevant oncogenic factor in DLBCL. TRIM37 was markedly upregulated in patient specimens and cell lines, and high expression correlated with poor prognosis. Loss-of-function studies showed that TRIM37 silencing suppressed proliferation and clonogenicity, triggered apoptosis, and restrained tumor growth in vivo. Mechanistically, TRIM37 promoted ubiquitin-proteasome degradation of the enhancer-associated histone methyltransferase KMT2D, reducing H3K4me1 deposition at the SOCS3 regulatory region, repressing SOCS3, and thereby sustaining JAK2-STAT3 phosphorylation. Rescue experiments supported causality: co-silencing KMT2D or enforcing TRIM37 expression reversed these effects, while JAK2 inhibitor treatment reproduced the impact of TRIM37 loss. Collectively, these findings show that TRIM37 drives DLBCL progression by destabilizing KMT2D to disable SOCS3-mediated negative feedback on JAK2-STAT3 and highlight TRIM37 as a potential therapeutic target.
科研通智能强力驱动
Strongly Powered by AbleSci AI